Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Early baby swimming linked to a small IQ advantage by preschool age

1

Sep 2026

Early baby swimming linked to a small IQ advantage by preschool age

A prospective cohort study of 1,935 mother-child pairs examined whether baby swimming during the first 6 months of life was associated with IQ and cognitive performance at ages 4 to 6 years. Swimming participation was associated with modestly higher scores across several cognitive domains, but the researchers cautioned that the observational findings cannot establish causation and may partly reflect socioeconomic and family-level differences.

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

1

Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

Adolescent binge drinking causes lasting changes in brain function

1

Sep 2026

Adolescent binge drinking causes lasting changes in brain function

New research from the Marshall University Joan C. Edwards School of Medicine provides insight into how binge alcohol exposure during adolescence may cause lasting changes in brain function that persist into adulthood, potentially identifying a new target for future treatment approaches.

What does more screen time mean for how children see and focus?

31

Aug 2026

What does more screen time mean for how children see and focus?

A cross-sectional study of children aged 4 to 9 found that greater caregiver-reported daily screen time was associated with lower contrast sensitivity and differences in how age related to visual-search performance. The associations varied by visual feature and task demands, suggesting that screen exposure may relate differently to lower-level visual processing and selective attention across middle childhood.

Semaglutide did more than cut weight in this analysis of 6,239 adults

31

Aug 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

New guideline updates medications for preventing migraine in adults

31

Aug 2026

New guideline updates medications for preventing migraine in adults

To help clinicians determine which medications may be most effective at preventing migraine in adults, the American Academy of Neurology (AAN) and American Headache Society (AHS) have issued a joint practice guideline update with evidence-based recommendations, published on August 31, 2026, in Neurology®, the medical journal of the American Academy of Neurology, and in Headache, the official journal of the American Headache Society.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.